Recruiting Schizophrenia Studies in Culver City
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia...
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population....
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants age...
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults....
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inade...
About Schizophrenia Clinical Trials in Culver City
Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.
There are currently 5 schizophrenia clinical trials recruiting participants in Culver City, CALIFORNIA. These studies are seeking a combined 1,716 participants. Research is being sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., Gedeon Richter Plc., MapLight Therapeutics and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Schizophrenia Clinical Trials in Culver City — FAQ
Are there schizophrenia clinical trials in Culver City?
Yes, there are 5 schizophrenia clinical trials currently recruiting in Culver City, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Culver City?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Culver City research site will contact you about next steps.
Are clinical trials in Culver City free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Culver City studies also compensate for your time and travel.
What schizophrenia treatments are being tested?
The 5 active trials in Culver City are testing new therapies including novel drugs, biologics, and treatment approaches for schizophrenia.
Data updated March 2, 2026 from ClinicalTrials.gov